Esperion
5 articles about Esperion
-
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
-
American College of Cardiology Program to Increase Cholesterol Screenings
9/12/2023
The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, "Driving Urgency in LDL Screening," to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular disease to help clinicians identify those who need treatment in accordance with medical guidelines.
-
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
6/22/2020
Esperion announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe.
-
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
3/19/2020
Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.
-
Esperion to Participate in Upcoming Investor Conferences
2/28/2020
Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences: